Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment
PURPOSE: Vismodegib is a Hedgehog pathway inhibitor approved for the treatment of advanced basal cell carcinoma. Currently, the pharmacokinetics (PK) and safety of vismodegib in patients with hepatic dysfunction are unknown and are the objective of this study. METHODS: Patients with advanced solid m...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Cancer Chemother Pharmacol |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
2017
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5520972/ https://ncbi.nlm.nih.gov/pubmed/28523596 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-017-3315-8 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|